Frantz EyeCare reports 98% of Light Adjustable Lens patients achieved refractive accuracy within ±0.50 D of target, exceeding published national cataract surgery benchmarks.
Publication|Slideshows|November 14, 2023
- Ophthalmology Times: November 2023
- Volume 48
- Issue 11
Optic Relief - 2023 Issues
Author(s)Jon Carter
The latest in Optic Relief from Ophthalmology Times
Advertisement
In every issue, we bring you some Optic Relief in the form of a comic by Jon Carter. Stay current on all the Optic Relief content from the 2023 issues!
Articles in this issue
almost 3 years ago
Virtual simulation training offers assistalmost 3 years ago
Editorial: Pulling back the veil of gender bias in the workplacealmost 3 years ago
When managing cases of dry eye, expect the unexpectedalmost 3 years ago
Ophthalmology can set pace for regulatory-grade real-world dataalmost 3 years ago
Two-year results of laser scleral microporationalmost 3 years ago
Image may be everything with ultrawidefield-guided swept-source OCTAdvertisement
Related to this article
In this Q&A, Ping Moore, OD, covers emerging dry eye therapies, from selenium sulfide to next-gen cyclosporine, and how subtype-guided care shapes treatment choices.
Ophthalmology is projected to face one of the steepest physician shortages of any subspecialty by 2038.
Two investigational pipeline therapies take aim at the root causes of dry eye disease
Dry eye care pivots to root-cause diagnosis and personalized biologics/devices,
Cataract surgery becomes refractive: learn how IOL choices and preop counseling across distance, intermediate and near turn 20/20 into 20/happy.
Findings from the third annual State of Dry Eye survey link symptom management to quality of life gains, including lower anxiety and improved self-confidence.
June brings FDA clearance for Lumvoa, key retina and glaucoma trials, device deals, and hard truths on AI performance in eye care.
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Brepocitinib meets all Phase 3 end points in noninfectious uveitis
2
Demodex blepharitis: Diagnosis, treatment response, and recurrence
3
Myopia control using spectacle lenses with highly aspherical lenslets
4
SpyGlass Pharma's BIM-IOL System holds 37% IOP reduction at 4 years in first-in-human trial
5